Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with
heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used …

Background: Sacubitril–valsartan has been shown to have superior effects over angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

Objective: A meta-analysis of the studies involving Sacubitril/Valsartan in chronic heart
failure was performed to compare the efficacy and safety of Sacubitril/Valsartan with …

Objective: The current meta-analysis reviews the different randomized controlled trials
(RCTs) on the use of sacubitril-valsartan (SV) thoroughly and assesses its effectiveness and …

We performed a meta-analysis investigating the efficacy and adverse effects of sacubitril–
valsartan in various types of heart failure including more recent studies and a larger sample …

Background: Sacubitril/valsartan is a first-in-class angiotensin-receptor neprilysin inhibitor
used to treat heart failure. The evidence for this novel medication is largely based on one …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

With an estimated 6.2 million adults affected in the USA, heart failure remains a leading
cause of morbidity, mortality, and health-care costs, despite the use of guideline-based …

Aims Practice guidelines recommend sacubitril/valsartan for heart failure with reduced
ejection fraction. The aim of our study was to describe the use of sacubitril/valsartan in real …

Since initial publication of the PARADIGM‐HF trial in 2014, sacubitril/valsartan has been
investigated in various settings to establish optimal use, further expanding its indications in …